

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 July 2023 (13.07.2023)



(10) International Publication Number
WO 2023/131720 A1

(51) International Patent Classification:

A61K 31/445 (2006.01) A61P 25/00 (2006.01)
A61K 45/06 (2006.01) A61P 25/28 (2006.01)

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:

PCT/EP2023/050459

(22) International Filing Date:

10 January 2023 (10.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

22150783.3 10 January 2022 (10.01.2022) EP
22193136.3 31 August 2022 (31.08.2022) EP

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))


(71) Applicant: **AZAFAROS B.V.** [NL/NL]; J.H. Oortweg 21,
2333 CH Leiden (NL).

(72) Inventors: **ROBIN, Jennifer**; c/o Azafaros B.V., J.H.
Oortweg 21, 2333 CH Leiden (NL). **BLATTER, Fritz**; c/
o Azafaros B.V., J.H. Oortweg 21, 2333 CH Leiden (NL).
HETT, Robert; c/o Azafaros B.V., J.H. Oortweg 21, 2333
CH Leiden (NL). **LANDSKRONER, Kyle**; c/o Azafaros
AG, Dufourstrasse 25, 4052 Basel (CH).

(74) Agent: **BOULT WADE TENNANT LLP**; Salisbury
Square House, 8 Salisbury Square, London EC4Y 8AP
(GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: TREATMENT OF GM2 GANGLIOSIDOSIS



(57) Abstract: The invention relates to a compound of formula (I), for use in treating GM2 gangliosidosis, specifically Sandhoff disease or Tay-Sachs disease. Specifically, the invention relates to a compound of formula (I) for use in increasing survival of a subject suffering from GM2 gangliosidosis, specifically Sandhoff disease or Tay-Sachs disease. The compound of formula (I) may also be used as an anti-inflammatory agent.

WO 2023/131720 A1